Since diabetes-mediated inflammation and VEGF are pivotal precursors to retinal vascular impairment and the progression of diabetic retinopathy (Tang and Kern, 2011; Gupta et al., 2013), ERK5 could be a potentially novel therapeutic target for diabetic retinopathy. Here, VEGFA is linked to diabetes mellitus.